Low-dose epcoritamab with GemOx for relapsed/refractory DLBCL

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a phase 2, single-center interventional trial combining low-dose epcoritamab (12 mg) with GemOx chemotherapy (gemcitabine 1000 mg/m2 plus oxaliplatin) for patients with relapsed or refractory diffuse large B‑cell lymphoma who are candidates for autologous stem cell transplant. Participants receive the combination regimen and are monitored for tumor response, safety, and tolerability. The study enrolls adults with ECOG 0–2 who have had at least one prior line of therapy and meet Lugano criteria for active disease. Treatment and follow-up occur at Hospital Universitario "Dr. José Eleuterio González" in Monterrey, Mexico.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects with relapsed/refractory diffuse large B-cell lymphoma who have received at least 1 previous line of treatment and that are candidates to autologous stem cell transplant
* ECOG 0-2
* Women of reproductive age who agree on getting a contraceptive method
* Subjects who fulfill Lugano´s criteria for disease activity
* Subjects who voluntarily accept to participate in this study

Exclusion Criteria:

* Active bacterial, viral or fungal infection
* Subjects who have already received an autologous o allogeneic stem cell transplantation
* Subjects with other active neoplasias
* Subjects with end-stage failure

Where it's running

• Hospital Universitario "Dr. José Eleuterio González"
  Monterrey, Nuevo León, Mexico Recruiting

Study contacts

• Principal investigator: Perla R Colunga-Pedraza, MD — Hospital Universitario "Dr. José Eleuterio González"
• Study coordinator: Perla R Colunga-Pedraza, MD
• Email: alrep_rcp@gmail.com
• Phone: +52 8110761973

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Pirtobrutinib and Epcoritamab vs R-(Mini)-CHOP for DLBCL-type Richter Transformation in older or frail adults

  This trial tests a fixed-duration treatment with Pirtobrutinib and Epcoritamab against a mini-CHOP regimen in adults age 80+ or who are frail with Richter transformation.

  Recruiting at 7 sites Phase 2 German CLL Study Group · Melbourne and 11 other locations · NCT07917780

• HMPL-760 with R‑GemOx versus placebo with R‑GemOx for relapsed or refractory diffuse large B‑cell lymphoma

  This trial will see if adding HMPL‑760 to R‑GemOx helps adults with relapsed or refractory diffuse large B‑cell lymphoma respond better or live longer than R‑GemOx plus placebo.

  Recruiting at 48 sites Phase 3 Hutchmed · Shanghai, Shanghai Municipality and 50 other locations · NCT07409428

• Epcoritamab plus R-GemOx before autologous stem cell transplant for relapsed or refractory DLBCL

  This phase II trial tests whether adding epcoritamab to rituximab with gemcitabine and oxaliplatin (R-GemOx) can help adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) achieve remission and proceed to autologous stem cell transplant.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT07365306

• NK cell therapy with epcoritamab and tafasitamab for relapsed or treatment‑resistant B‑cell lymphoma

  This trial will try whether adding donor-derived ONC-PluReceptor NK cells to the antibodies epcoritamab and tafasitamab helps control relapsed or refractory CD19/CD20-positive B‑cell non‑Hodgkin lymphoma.

  Recruiting Phase 1/2 M.D. Anderson Cancer Center · Houston, Texas · NCT07283679

• Venetoclax plus obinutuzumab followed by epcoritamab for untreated CLL/SLL

  This trial tests whether giving venetoclax and obinutuzumab followed by epcoritamab can produce deep remissions in people with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma.

  Recruiting at 4 sites Phase 2 City of Hope Medical Center · Duarte, California and 6 other locations · NCT07218510

• Combining loncastuximab tesirine and epcoritamab in relapsed/refractory aggressive B‑cell lymphoma

  In this phase 2 study, researchers will test whether the drug combo loncastuximab tesirine plus epcoritamab can help people with relapsed or refractory aggressive B‑cell lymphomas, including DLBCL, HGBL, or FL 3B, who have failed prior therapies or CAR‑T treatment.

  Recruiting at 30 sites Phase 2 Universität Münster · Aachen and 33 other locations · NCT07197307

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.